Abstract
To assess the drug interaction between oral solution itraconazole and calcineurin inhibitors, 10 recipients of allogeneic hematopoietic stem cell transplantation (HSCT), in whom oral solution itraconazole was started when they had been on a steady dose of calcineurin inhibitors (cyclosporine A or tacrolimus), were retrospectively evaluated. The concentration/dose [C/D; (ng/mL)/(mg/kg)] ratio of calcineurin inhibitors significantly increased after initiating oral solution itraconazole, and the increase at 7–10 days after initiating itraconazole was 93.7%, ranging from 37.3 to 328.2%. The plasma level of itraconazole/hydroxyitraconazole was significantly correlated with the increase in the C/D ratio of calcineurin inhibitors (correlation coefficient, 0.65; P < 0.05). These results suggest that oral solution itraconazole significantly interacts with calcineurin inhibitors with a wide interindividual variability in allogeneic HSCT recipients, which could partly be explained by the variable bioavailability of oral solution itraconazole.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Dykewicz CA, Jaffe HW. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant. 2006;6:670–2.
Marr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis. 2002;34:909–17. doi:10.1086/339202.
Kami M, Machida U, Okuzumi K, Matsumura T, Mori Si S, Hori A, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol. 2002;117:40–6. doi:10.1046/j.1365-2141.2002.03414.x.
Winston DJ, Maziarz RT, Chandrasekar PH, Lazarus HM, Goldman M, Blumer JL, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003;138:705–13.
Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–33. doi:10.1182/blood-2003-08-2644.
Ito Y, Ohyashiki K, Yoshida I, Takeuchi M, Aoyama Y, Mugitani A, et al. The prophylactic effect of itraconazole capsules and fluconazole capsules for systemic fungal infections in patients with acute myeloid leukemia and myelodysplastic syndromes: a Japanese multicenter randomized, controlled study. Int J Hematol. 2007;85:121–7. doi:10.1532/IJH97.06079.
Saad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy. 2006;26:1730–44. doi:10.1592/phco.26.12.1730.
Mahnke CB, Sutton RM, Venkataramanan R, Michaels M, Kurland G, Boyle GJ, et al. Tacrolimus dosage requirements after initiation of azole antifungal therapy in pediatric thoracic organ transplantation. Pediatr Transplant. 2003;7:474–8. doi:10.1046/j.1397-3142.2003.00103.x.
Leather H, Boyette RM, Tian L, Wingard JR. Pharmacokinetic evaluation of the drug interaction between intravenous itraconazole and intravenous tacrolimus or intravenous cyclosporin A in allogeneic hematopoietic stem cell transplant recipients. Biol Bone Marrow Transplant. 2006;12:325–34. doi:10.1016/j.bbmt.2005.10.022.
Uno T, Shimizu M, Sugawara K, Tateishi T. Sensitive determination of itraconazole and its active metabolite in human plasma by column-switching high-performance liquid chromatography with ultraviolet detection. Ther Drug Monit. 2006;28:526–31. doi:10.1097/00007691-200608000-00007.
Kanbayashi Y, Nomura K, Fujimoto Y, Shimura K, Shimizu D, Okamoto K, et al. Population pharmacokinetics of itraconazole solution used as prophylaxis for febrile neutropenia. Int J Antimicrob Agents. 2008;31:452–7. doi:10.1016/j.ijantimicag.2007.12.017.
Kwan JTC, Foxall PJD, Davidson DGC, Bending MR, Eisinger AJ. Interaction of cyclosporin and itraconazole. Lancet. 1987;2:282. doi:10.1016/S0140-6736(87)90873-7.
Kramer MR, Marshall SE, Denning DW, Keogh AM, Tucker RM, Galgiani JN, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med. 1990;113:327–9.
Kramer MR, Merin G, Rudis E, Bar I, Nesher T, Bublil M, et al. Dose adjustment and cost of itraconazole prophylaxis in lung transplant recipients receiving cyclosporine and tacrolimus (FK 506). Transplant Proc. 1997;29:2657–9. doi:10.1016/S0041-1345(97)00546-0.
Billaud EM, Guillemain R, Tacco F, Chevalier P. Evidence for a pharmacokinetic interaction between itraconazole and tacrolimus in organ transplant patients. Br J Clin Pharmacol. 1998;46:271–2. doi:10.1046/j.1365-2125.1998.00784.x.
Capone D, Gentile A, Imperatore P, Palmiero G, Basile V. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother. 1999;33:1124–5. doi:10.1345/aph.18409.
Banerjee R, Leaver N, Lyster H, Banner NR. Coadministration of itraconazole and tacrolimus after thoracic organ transplantation. Transplant Proc. 2001;33:1600–2.
Cervelli MJ, Russ GR. Itraconazole–tacrolimus drug interaction. Ther Drug Monit. 2003;25:483–4. doi:10.1097/00007691-200308000-00012.
Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother. 2005;56(Suppl S1):i17–22.
Bradford CR, Prentice AG, Warnock DW, Copplestone JA. Comparison of the multiple dose pharmacokinetics of two formulations of itraconazole during remission induction for acute myeloblastic leukaemia. J Antimicrob Chemother. 1991;28:555–60. doi:10.1093/jac/28.4.555.
Prentice AG, Warnock DW. Itraconazole more bioavailable in solution. Blood. 1996;88:3662–3.
Potter M, Donnelly JP. The role of itraconazole in preventing and treating systemic fungal infections in immunocompromised patients. Acta Haematol Acta Haematol. 2004;111:175–80.
Boogaerts MA, Verhoef GE, Zachee P, Demuynck H, Verbist L, De Beule K. Antifungal prophylaxis with itraconazole in prolonged neutropenia: correlation with plasma levels. Mycoses. 1989;32(Suppl 1):103–8.
Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis. 1989;9(Suppl 1):S94–9.
British Society for Antimicrobial Chemotherapy Working Party. Laboratory monitoring of antifungal chemotherapy. Lancet. 1991;337:1577–80.
Prentice AG, Warnock DW, Johnson SA, Phillips MJ, Oliver DA. Multiple-dose pharmacokinetics of an oral solution of itraconazole in autologous bone marrow transplant recipients. J Antimicrob Chemother. 1994;34:247–52. doi:10.1093/jac/34.2.247.
Grigg AP, Brown M, Roberts AW, Szer J, Slavin MA. A pilot study of targeted itraconazole prophylaxis in patients with graft-versus-host disease at high risk of invasive mould infections following allogeneic stem cell transplantation. Bone Marrow Transplant. 2004;34:447–53. doi:10.1038/sj.bmt.1704614.
Acknowledgments
This study was supported in part by grants from the Nagao Memorial Fund.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Mori, T., Aisa, Y., Kato, J. et al. Drug interaction between oral solution itraconazole and calcineurin inhibitors in allogeneic hematopoietic stem cell transplantation recipients: an association with bioavailability of oral solution itraconazole. Int J Hematol 90, 103–107 (2009). https://doi.org/10.1007/s12185-009-0344-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-009-0344-z